Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV/AIDS Treatment Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users

NCT03584282
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication, Drug Use
Interventions
Text Messaging, Peer Navigation
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

NCT00238459
View directory record Official record
Conditions
HIV Infections
Interventions
Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

NCT02175680
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140, Historical data
Drug · Other
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

CAR-T Cells for HIV Infection

NCT04648046
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Drug · Biological · Other
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Education and Employment Support for HIV Prevention in Young Adults (ENSPIRE)

NCT06096324
View directory record Official record
Conditions
Economic Hardship, Condomless Sex, Utilization, Health Care
Interventions
Job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring., Job announcements
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

NCT00000923
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

NCT00001044
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
4
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Results available

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

NCT00662545
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Results available

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802
View directory record Official record
Conditions
HIV
Interventions
Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

NCT00000819
View directory record Official record
Conditions
HIV Infections, AIDS-Associated Nephropathy
Interventions
Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Screening HIV-Infected Patients for Vaccine Studies

NCT00051519
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

NCT00000844
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
15
States / cities
Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Phase 3 Interventional

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
16
States / cities
San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

NCT00000842
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Nerve Growth Factor, Recombinant Human
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
14
States / cities
Los Angeles, California • San Mateo, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

NCT00038480
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 6 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
14
States / cities
Oakland, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Immune Restoration by Lipoic Acid in AIDS

NCT00033176
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Role of Positive Affect in Adjustment to HIV

NCT00582023
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

NCT00824369
View directory record Official record
Conditions
HIV-1
Interventions
No drug will be administered
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Sacramento, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Phase 2 Interventional

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

NCT00299897
View directory record Official record
Conditions
HIV Infections, Human Immunodeficiency Virus
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 27, 2026, 4:56 AM EDT